Abstract
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Similarly, a number of highly conserved viral proteins for structure, replication, and fidelity are 17 also maintained in the CoV backbone (7). Among these, MERS-CoV NSP16 provides a potent 
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2
Consistent with previous studies in SARS-CoV (10), the dNSP16 MERS-CoV mutant 3 maintained no significant attenuation in terms of replication or the initial host immune response.
4
However, both primary human airway epithelial cells and in vivo studies in a MERS-CoV mouse 5 model demonstrated robust attenuation of dNSP16 mutant growth and pathogenesis. Notably, 6 attenuation was both IFN and IFIT1 dependent providing a clear mechanism for attenuation.
7
Importantly, the dNSP16 mutant also provided robust protection against a lethal MERS-CoV 8 challenge and maintained attenuation in the mouse adapted backbone. Together, the results
9
illustrate the broad conservation and necessity of NSP16 in CoV pathogenesis and highlight
10
targeting this protein as a rapid response platform for future emergent CoV strains.
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Results

1
A combination of structural and biochemical approaches has established a critical role for CoV 2 NSP16 in 2'O methyltransferase activity (Fig. 1A) . Stabilized by interactions with NSP10 3 (orange), NSP16 relies on a highly conserved KDKE motif (red) to mediate its activity (11).
4
Previous alteration of this motif in both group 2b SARS-CoV (10) and group 2a MHV (9) 5 disrupted 2'O methyltransferase activity and attenuated varying aspects of infection. Based on 6 high conservation across the CoV family (Fig. 1B) , we hypothesized that disruption of the KDKE 7 motif would also attenuate other emerging CoV families, including the group 2c MERS-CoV.
8
Utilizing a MERS-CoV reversed genetic system (12), we disrupted the KDKE motif by mutating 9 two nucleotides to produce a D130A change (Fig. 1A) . The resulting disrupted NSP16 mutant 10 (dNSP16) had no significant defect noted in stock titer generation (not shown); similarly, low
11
MOI infection of both Vero cells and Calu3 cells, a respiratory epithelial cell line, demonstrated
12
only modest attenuation at late time points (Fig. 1C & D) . Together, these results indicate that
13
NSP16 activity is not required for replication capacity.
14
In vitro host response similar between SARS and MERS dNSP16 mutants.
15
Having established replication competence in both Vero and Calu3 cells, we next evaluated (Fig. 2) .
21
Over the first 24 hours of infection, both MERS-CoV and SARS-CoV dNSP16 showed no 22 significant functional enrichment of any categories relative to corresponding wild-type (WT) 23 infections, consistent with the lack of replication attenuation. However, at late times (>24 hours 24 post infection), SARS-CoV produces robust changes in several host pathways including 25 cytokine responses, inflammation, and extracellular activity. Similarly, changes in apoptosis,
26
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5
MERS-CoV dNSP16 attenuated in primary and in vivo models.
6
To further examine the replicative capacity of dNSP16, we infected both human airway models 7 and mice expressing human dipeptidyl peptidase 4 (DPP4), the receptor for MERS-CoV.
8
Primary human airway cultures (HAE) were challenged with wild-type and dNSP16 MERS-CoV 9 at a low MOI (Fig. 3A) . While robust replication was observed following wild-type infection, 10 dNSP16 MERS mutant had significant attenuation that corresponded well to previous results
11
seen with SARS-CoV dNSP16 (10). We next examined MERS dNSP16 replication phenotypes 12 in the context of in vivo infection using an adenovirus transduction model of BALB/c mice (13).
13
While neither infection produced weight loss (not shown), WT MERS-CoV replicated efficiently 14 at both day 2 and day 4 post infection (Fig. 3B) 
21
activity severely attenuated dNSP16 replication at both day 2 and day 4 post infection ( Fig. 3C ).
22
Coupled with data from HAE cultures and the adenovirus model, the results demonstrate clear 23 attenuation of MERS dNSP16 relative to control.
24
dNSP16 MERS-CoV attenuation mediated by IFN and IFIT1.
25
Having established a deficit in MERS NSP16 mutant replication in relevant in vitro and in vivo 1 models, we next sought to evaluate the mechanism of attenuation. Previous work by our lab and 2 others had established increased susceptibility of NSP16 mutants to type I IFN (9, 10). While 3 both viruses were sensitive to IFN treatment, the MERS dNSP16 mutant had a significant 4 reduction in viral replication relative to control virus (Fig. 4A) The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/173286 doi: bioRxiv preprint vaccine platform that not only induces high levels of neutralizing antibodies, but provides 1 compete protection from lethal MERS-CoV challenge.
2
NSP16 mutation attenuates mouse adapted MERS-CoV.
3
Despite conferring protection in the wild-type MERS-CoV backbone, it was unclear if the NSP16 4 mutant would be sufficiently attenuated in a virulent MERS backbone. To address this question,
5
we inserted the dNSP16 mutation (D130A) into the mouse adapted MERS-CoV backbone (14).
6
Following infection, mouse adapted icMERS-CoV produced rapid weight loss and lethality ( Fig.   7   6A ). In contrast, the mouse adapted dNSP16 mutant had only modest weight loss and 100% 8 survival following infection. In addition, viral replication of the dNSP16 mutant was significantly 9 attenuated relative to WT at days 2 and 4 post infection (Fig. 6B) . Finally, hemorrhage scoring 10 of the lung revealed minimal disease in dNSP16 relative to control mice at day 4 post infection
11
( Fig. 6C) . Overall, the results demonstrate robust attenuation of MERS-CoV pathogenesis in the 12 context a NSP16 mutation.
14
Discussion
1
In the context of the ongoing MERS-CoV outbreak, the development of universal 2 platform strategies to attenuate emerging and contemporary coronaviruses is a significant The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. 
25
While further vaccine characterization is required, the results indicate that disruption of CoV
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(IACUC Protocol #15-009 and 13-072) followed in this manuscript.
25
10
Animal housing, care and experimental protocols were in accordance with University of North
11
Carolina (UNC) Institutional Animal Care and Use Committee (IACUC) guidelines.
12
Data Dissemination. Raw microarray data for these studies were deposited in publicly 13 available databases in the National Center for Biotechnology Information's (NCBI) Gene
14
Expression Omnibus (35) and are accessible through GEO Series: GSE65574.
15
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65574).
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Homology models were created using Modeller in the Max-Planck Institute's Bioinformatics 6 Toolkit. The known crystal structure for the NSP10/16 complex (3R24 in the RCSB protein data 7 bank) was used as the template structure (Chen et al., 2011) . Homology models were then 8 manipulated using MacPyMol. B) Heat maps were constructed from a set of representative 9 coronaviruses from all four genogroups using alignment data paired with neighbor-joining 10 phylogenetic trees built in Geneious (v.9.1.5) and visualized in EvolView (evolgenius.info). The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/173286 doi: bioRxiv preprint Figure 1. NSP16 highly conserved across coronavirus family. A) NSP16-NSP10 complex for MERS-CoV. NSP16 (gray) highlighting the conserved KDKE motif (red) required for 2'O methyltransferase activity. Also shown, required NSP10 scaffold for MERS-CoV (orange). Inset displays conserved KDKE (right) as well as D130A (left) mutation that disrupts function. Homology models were created using Modeller in the Max-Planck Institute's Bioinformatics Toolkit. The known crystal structure for the NSP10/16 complex (3R24 in the RCSB protein data bank) was used as the template structure (Chen et al., 2011) . Homology models were then manipulated using MacPyMol. B) Heat maps were constructed from a set of representative coronaviruses from all four genogroups using alignment data paired with neighbor-joining phylogenetic trees built in Geneious (v.9.1.5) and visualized in EvolView The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/173286 doi: bioRxiv preprint The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/173286 doi: bioRxiv preprint Figure 5 . MERS dNSP16 mutants protects from lethal challenge. A) Weight loss, B) day 4 viral -ter, and C) hemorrhage score following challenge of 288-330+/+ CRISPR/Cas9 mice vaccinated with wild-type MERS dNSP16 (red) or mock (black) with 10^6 pfu passaged mouse adapted . D) Plaque reduc-on neutraliza-on with sera from WT (black) or dNSP16 (red) vaccinated mice. P-value representa-ve of Student's T-test with values represen-ng *< 0.05 ** <0.01 *** <0.001.
The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/173286 doi: bioRxiv preprint Figure 6 . MERS dNSP16 mutant aAenuated in virulent mouse adapted MERS-CoV strain. A) Weight loss, B) lung -ters, and C) hemorrhage score following infec-on of 288-330 +/+ CRISPR/Cas9 mice infected with 10^6 pfu MERS-CoV MA1 (black) or dNSP16 MA1 (red) at day 2 and 4. C) P-value representa-ve of Student's T-test with values represen-ng *< 0.05 ** <0.01 *** <0.001.
